Skip to main content
SpringerLink
Log in

Neurotoxicité périphérique des traitements oncologiques: aspects précliniques et cliniques

  • Chapter
Aider á vivre aprés un cancer

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 391 Accesses

Résumé

En dehors des toxicités aiguës, souvent transitoires et d’ordre surtout digestif, on retrouve, parmi les principaux effets secondaires entraînant l’arrêt ou le changement d’un traitement anticancéreux, par ordre de fréquence: les toxicités hématologiques, les toxicités rénales et les toxicités neurologiques (1). Si les deux premiéres peuvent être maîtrisées par l’adjonction de facteurs de croissance hématopoïétique et l’hyperhydratation, la toxicité neurologique est diffi cilement contournable, et devient pour certains produits dose-limitante. Le probléme est d’autant plus crucial que les produits concernés sont d’utilisation ancienne avec une effi cacité bien établie (cisplatine, vincristine, etc.) (1) ou d’introduction beaucoup plus récente avec un spectre d’action qui ne cesse de s’élargir (taxanes, oxaliplatine). En outre, les nouveaux produits arrivant sur le marché, démontrent dans les premiéres études un fort potentiel neurotoxique (2).

Cet article a fait l’objet d’une publication dans la revue Oncologie (2006) 8: 895–900, Springer-Verlag France.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249: 9–17

    Article  PubMed  CAS  Google Scholar 

  2. Lee JJ, Swain SM (2006) Perpiheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24: 1633–42

    Article  PubMed  CAS  Google Scholar 

  3. Balayssac D, Cayre A, Authier N, et al. (2006) Involvement of the multidrug resistance transporters in cisplatin-induced neuropathy in rats. Comparison with the chronic constriction injury model and monoarthritic rats. Eur J Pharmacol 544(1–3): 49–57

    Article  PubMed  CAS  Google Scholar 

  4. Cata JP, Weng HR, Lee BN, et al. (2006) Clinical and experimental fi ndings in humans and animals with chemotherapy-induced peripheral neuropathy. Min Anesthesiol 72: 151–69

    CAS  Google Scholar 

  5. Postma J (1995) Paclitaxel-induced neuropathy. Ann Oncol 6: 489–94

    PubMed  CAS  Google Scholar 

  6. Von der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, et al. (1990) Incidence of neuropathy in 395 patients with ovarian cancer treated with or without Cisplatin. Cancer 66: 1697–1702

    Article  PubMed  Google Scholar 

  7. Strumberg D, Brugge S, Korn MW, et al. (2002) Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 13: 229–36

    Article  PubMed  CAS  Google Scholar 

  8. Gamelin L, Boisdron-Celle M, Morel A, et al. (2006) Oxaliplatin neurotoxicity. Bulletin du cancer 93: S17–S22

    PubMed  CAS  Google Scholar 

  9. Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanisms of action and biologic activity. J Clin Oncol 22: 2015–25

    Article  PubMed  CAS  Google Scholar 

  10. Zhuang SH, Agrawal M, Edgerly M, et al. (2005) A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 103: 1932–8

    Article  PubMed  CAS  Google Scholar 

  11. Faivre S, Delbado C, Boige V, et al. (2008) Safety of repeated administration of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies. Eur J Cancer 44: 674–82

    Article  PubMed  CAS  Google Scholar 

  12. Badros A, Goloubeva O, Dalal JS, et al. (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110(5): 1042–8.

    Article  PubMed  CAS  Google Scholar 

  13. Harousseau JL (2006) Thalidomide in multiple myeloma: past, present and future. Futur Oncol 2: 577–89

    Article  CAS  Google Scholar 

  14. Kannarkat G, Lasher EE, Schiff D (2007) Neurologic complications of chemotherapy agents. Curr Opin Neurol 20: 719–25

    PubMed  CAS  Google Scholar 

  15. Argyriou AA, Polychronopoulos P, Koutras A, et al. (2006) Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 14: 223–9

    Article  PubMed  Google Scholar 

  16. Du Bois A, Schlaich M, Luck HJ, et al. (1999) Evaluation of neurotoxicity induced by Paclitaxel second-line chemotherapy. Support Care Cancer 7: 354–61

    Article  PubMed  Google Scholar 

  17. LoMonaco M, Milano M, Batocchi, et al. (1992) Cisplatin neuropathy: clinical course and neurophysiological fi ndings. J Neurol 239: 199–204

    Article  PubMed  CAS  Google Scholar 

  18. Chaudhry V, Rowinsky EK, Sartorius SE, et al. (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35: 304–11

    Article  PubMed  CAS  Google Scholar 

  19. Krishnan AV, Goldstein D, Friedlander M, et al. (2006) Oxaliplatin and axonal Na function in vivo. Clin Cancer Res 12: 4481–4

    Article  PubMed  CAS  Google Scholar 

  20. Oldenburg J, Fossa SD, Dahl AA, et al. (2006) Scale for chemotherapy-induced long-term neurotoxicity: psychometrics, validation, and fi ndings in a large sample of testicular cancer survivors. Qual Life Res 15: 791–800

    Article  PubMed  Google Scholar 

  21. Postma J (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11: 509–13

    Article  PubMed  CAS  Google Scholar 

  22. Cavaletti G, Frigeni B, Lanzani F, et al. (2007) The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 12(3): 210–5

    Article  PubMed  Google Scholar 

  23. Ja’afer FM, Hamdan FB, Mohammed FH (2006) Vincristine-induced neuropathy in rat: electrophysiological and histological study. Exp Brain Res 173: 334–45

    Article  CAS  Google Scholar 

  24. Authier N, Gillet JP, Eschalier A, et al. (2003) A new animal model of vincristine-induced nociceptive peripheral neuropathy. Neurotoxicology 24: 797–805

    Article  PubMed  CAS  Google Scholar 

  25. Joseph EK and Levine JD (2006) Mitochondrial electron transport in models of neuropathic and infl ammatory pain. Pain 121: 105–14

    Article  PubMed  CAS  Google Scholar 

  26. Kamei J, Tamura N, Saitoh A (2005) Possible involvement of the spinal nitric oxide/ cGMP pathway in vincristine-induced painful neuropathy in mice. Pain 117: 112–20

    Article  PubMed  CAS  Google Scholar 

  27. Lynch JJ, Wade CL, Zhong CM, et al. (2004) Attenuation of mechanical allodynie by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain 110: 56–63

    Article  PubMed  CAS  Google Scholar 

  28. Persohn E, Canta A, Schoepfer S, et al. (2005) Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 41: 1460–6

    Article  PubMed  CAS  Google Scholar 

  29. Authier N, Gillet JP, Eschalier A, et al. (2000). Description of a short-term taxol-induced nociceptive neuropathy in rats. Brain Res 887: 239–49

    Article  PubMed  CAS  Google Scholar 

  30. Sissung TM, Mross K, Steinberg SM, et al. (2006) Association of ABCB1 genotype with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42(17): 2893–6

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  31. Flatters SJ, Bennett GJ (2006) Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 122: 245–57

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  32. Flatters SJ, Bennett GJ (2004) Ethosuximide reverses paclitaxel-and vincristine-induced painful peripheral neuropathy. Pain 109: 150–61

    Article  PubMed  CAS  Google Scholar 

  33. Verdu E, Vilches JJ, Rodriguez FJ, et al. (1999) Physiological and immunohistological characterization of cisplatin-induced neuropathy in mice. Muscle Nerve 22: 329–40

    Article  PubMed  CAS  Google Scholar 

  34. Barajon I, Bersani M, Quartu M, et al. (1996) Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuropathy. Exp Neurol 138: 93–104

    Article  PubMed  CAS  Google Scholar 

  35. Authier N, Gillet JP, Eschalier A, et al. (2003) An animal model of nociceptive peripheral neuropathy following cisplatin repeated injections. Exp Neurol 1825: 12–20

    Article  CAS  Google Scholar 

  36. Kirchmair R, Walter DH, Ii M, et al. (2005) Antiangiogenesis mediates cisplatin-induced peripheral neuropathy. Circulation 111: 2662–70

    Article  PubMed  CAS  Google Scholar 

  37. Tomaszewski A, Büsselberg D (2006) Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats. Neurotoxicology 28(1): 49–58

    Article  PubMed  CAS  Google Scholar 

  38. Oztürk G, Erdogan E, Anlar O, et al. (2005) Effect of leukemia inhibitory factor in experimental cisplatin neuropathy in mice. Cytokine 29: 31–41

    PubMed  Google Scholar 

  39. Rodriguez-Menendez V, Gilardini A, Bossi M, et al. (2008) Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study. Anticancer Res 28: 335–42

    PubMed  CAS  Google Scholar 

  40. Jamieson SM, Liu J, Connor B, et al. (2005) Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 56: 391–9

    Article  PubMed  CAS  Google Scholar 

  41. Ling B, Authier N, Balayssac D, et al. (2007) Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 128(3): 225–34

    Article  PubMed  CAS  Google Scholar 

  42. Ling B, Coudore-civiale MA, Balayssac D, et al. (2007) Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. Toxicology 234(3): 176–84

    Article  PubMed  CAS  Google Scholar 

  43. Ta LE, Espeset L, Podratz J, et al. (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27(6): 922–1002

    Article  CAS  Google Scholar 

  44. Joseph EK, Chen X, Bogen O, et al. (2008) Oxaliplatin acts on IB4-positive nociceptors to induce an oxydative stress-dependent acute painful peripheral neuropathy. J Pain 9(5): 463–72

    Article  PubMed  CAS  Google Scholar 

  45. Cavaletti G, Gilardini A, Canta A, et al. (2007) Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in rat. Exp Neurol 204: 317–25

    Article  PubMed  CAS  Google Scholar 

  46. Stillman M, Cata JP (2006) Management of chemotherapy induced peripheral neuropathy. Curr Pain Headache Rep 10: 279–87

    Article  PubMed  Google Scholar 

  47. Wolf S, Barton D, Kottschade L, et al. (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44(11): 1507–15

    Article  PubMed  CAS  Google Scholar 

  48. Attal N, Cruccu G, Haanpää M, et al. (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13(11): 1153–69

    Article  PubMed  CAS  Google Scholar 

  49. Pignata S, De Placido S, Biamonte R, et al. (2006) Residual neurotoxicity in ovarian cancer patients in clinical remission after fi rst-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial Ovarian cancer retrospective study. BMC Cancer 6: 5

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  50. Siegal T, Haim N (1990) Cisplatin-induced peripheral neuropathy: frequent off-therapy deterioration, demyelinating syndromes and muscle cramps. Cancer 66: 1117–23

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculté de médecine et de pharmacie, UMR INSERM 766, BP 38, 63001, Clermont-Ferrand

    Nicolas Authier, Bing Ling, David Balayssac & Alain Eschalier

Authors
  1. Nicolas Authier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bing Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Balayssac
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alain Eschalier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France

About this chapter

Cite this chapter

Authier, N., Ling, B., Balayssac, D., Eschalier, A. (2010). Neurotoxicité périphérique des traitements oncologiques: aspects précliniques et cliniques. In: Aider á vivre aprés un cancer. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-79501-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-79501-5_17

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-79500-8

  • Online ISBN: 978-2-287-79501-5

Publish with us

Policies and ethics

Search

Navigation